Market updates for Bloom Energy, Moderna, and various biotech firms

Various companies across the energy and biotechnology sectors are seeing shifts in analyst ratings and market evaluations.

Bloom Energy is seeing increased demand for its hydrogen fuel cells due to the expansion of artificial intelligence infrastructure, which requires off-grid power solutions. While its product backlog has grown significantly, much of its value is tied to long-term service contracts.

In the biotechnology sector, Maravai LifeSciences received a downgrade from Wall Street Zen to a 'hold' rating, despite mixed views from other firms. Mirum Pharmaceuticals saw its 'market outperform' rating reiterated by Citizens Jmp with a $137.00 target price. Moderna was upgraded by Argus from 'hold' to 'buy' with a $180.00 price target, though it maintains an average 'hold' rating from the broader market.

Roivant Sciences also received positive attention, with HC Wainwright reiterating a 'buy' rating and a $41.00 target price, contributing to a consensus 'moderate buy' rating.